Long-Term Persistence of Olfactory and Gustatory Disorders in COVID-19 Patients.
COVID-19
SARS-CoV-2
long COVID
persistence
smell
taste
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
10
2021
accepted:
04
02
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
15
3
2022
Statut:
epublish
Résumé
Smell and taste disorders are frequent symptoms during acute COVID-19 and may persist long after the resolution of the initial phase. This study aims to estimate the proportion and risk factors for smell and/or taste disorders at the onset of symptoms and their persistence after more than 6 months of follow-up in COVID-19 patients. We analyzed a prospective cohort of COVID-19 patients admitted to our institute in Marseille, France in early 2020. After being discharged from the hospital, patients with smell and/or taste disorders were contacted for a telephone interview. Logistic regression analysis was performed to determine the risk factors for smell and/or taste disorders. A total of 3,737 patients were included, of whom 1,676 reported smell and/or taste disorders at the onset of symptoms. Taste and/or smell disorders were independently associated with being younger and female, a lower likelihood of suffering from diabetes, cardiovascular diseases and cancer, a longer delay between the onset of symptoms and consultation, and non-severe forms of COVID-19 at admission. Of the 605 patients with smell and/or taste disorders who were followed-up, 154 (25.5%) reported the persistence of symptoms for more than 6 months. At the time of follow-up, being female, having a chronic respiratory disease and using angiotensin-converting enzyme inhibitors (ACEis) were factors independently associated with the persistence of smell and/or taste disorders. In conclusion, the long-term persistence of olfactory and gustative disorders is frequent among COVID-19 patients, notably affecting female patients and patients who suffered from chronic respiratory diseases before infection. The role of ACEis needs to be further evaluated in larger numbers of patients.
Identifiants
pubmed: 35280874
doi: 10.3389/fmed.2022.794550
pmc: PMC8915119
doi:
Types de publication
Journal Article
Langues
eng
Pagination
794550Informations de copyright
Copyright © 2022 Nguyen, Hoang, Dao, Meddeb, Cortaredona, Lagier, Million, Raoult and Gautret.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Exp Otorhinolaryngol. 2021 Feb;14(1):88-92
pubmed: 32575977
N Engl J Med. 2020 Aug 6;383(6):e38
pubmed: 32502334
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261
pubmed: 32253535
Travel Med Infect Dis. 2020 Jul - Aug;36:101791
pubmed: 32593867
Cochrane Database Syst Rev. 2021 Jul 22;7:CD013877
pubmed: 34291812
Laryngoscope. 2014 Apr;124(4):826-31
pubmed: 23929687
Clin Microbiol Infect. 2021 Jun;27(6):931-932
pubmed: 33418020
Intensive Care Med. 2020 Feb;46(2):357-360
pubmed: 32025779
Nat Med. 2020 Jul;26(7):1037-1040
pubmed: 32393804
EClinicalMedicine. 2021 Aug;38:101019
pubmed: 34308300
Travel Med Infect Dis. 2020 Jul - Aug;36:101632
pubmed: 32205269
Curr Probl Cardiol. 2020 Aug;45(8):100618
pubmed: 32439197
Front Psychol. 2019 Feb 13;10:242
pubmed: 30814965
Laryngoscope. 2015 Aug;125(8):1763-6
pubmed: 26031472
Laryngoscope. 2019 Aug;129(8):1737-1743
pubmed: 30848489
Eur Arch Otorhinolaryngol. 2021 Aug;278(8):3113-3117
pubmed: 33423106
JAMA Netw Open. 2021 Jul 1;4(7):e2118717
pubmed: 34323987
Mayo Clin Proc. 2020 Aug;95(8):1621-1631
pubmed: 32753137
Eur Arch Otorhinolaryngol. 2015 Aug;272(8):1937-44
pubmed: 25238811
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
Int J Infect Dis. 2020 Sep;98:347-352
pubmed: 32615326
Nat Med. 2021 May;27(5):892-903
pubmed: 33767405